Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ProSomnus, Inc. - Common Stock (NQ: OSA )

1.040 +0.060 (+6.12%)
Streaming Delayed Price Updated: 3:51 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,128
Open 1.000
Bid (Size) 0.9206 (3)
Ask (Size) 1.120 (10)
Prev. Close 0.9800
Today's Range 0.9600 - 1.040
52wk Range 0.9100 - 9.410
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Roth MKM Maintains Buy Rating for ProSomnus: Here's What You Need To Know
Via Benzinga
ProSomnus Raises $10 Million To Fuel Growth and Optimize Operations
Company will leverage new capital inflow to optimize core business operations, advance strategic growth initiatives, and achieve cash flow breakeven 
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire

Performance

YTD
-82.24%
-82.24%
1 Month
-0.95%
-0.95%
3 Month
-66.45%
-66.45%
6 Month
-80.04%
-80.04%
1 Year
-84.71%
-84.71%

More News

Read More
EXCLUSIVE: Sleep Disorder Focused ProSomnus Raises $10M To Fuel Growth, Optimize Operations
Via Benzinga
ProSomnus Precision Obstructive Sleep Apnea Devices to be Featured in Scientific Abstracts and Podium Presentations at Upcoming Medical Conferences
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
Earnings Scheduled For August 3, 2023
Via Benzinga
Updated Clinical Trial Data Indicates Precision Oral Appliance Therapy with ProSomnus Devices is Non-Inferior to CPAP Therapy for the Treatment of Moderate to Severe Obstructive Sleep Apnea
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
EXCLUSIVE: ProSomnus' Device Therapy Better Than Philip's Device(s) For Sleep-Related Breathing Disorder, Study Shows
Via Benzinga
Why Avalo Therapeutics Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
Via Benzinga
ProSomnus Reports Record Second Quarter 2023 Top-Line Financial Results
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
EXCLUSIVE: ProSomnus Reports Much Smaller Than Expected Q2 Loss, Revenues Inline With Consensus
Via Benzinga
ProSomnus to Design Head-to-Head Clinical Trial vs. Hypoglossal Nerve Stimulation
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus Announces Second Quarter 2023 Investor Call and Business Update
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
71% of Self-identified Snorers Have Never Consulted a Healthcare Professional
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
Data Presented at the 2023 SLEEP Annual Meeting Strengthens Evidence for ProSomnus Precision Oral Appliance Therapy for the Treatment of Obstructive Sleep Apnea
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
Data Presented at the 2023 American Academy of Dental Sleep Medicine and the American Thoracic Society Meetings Further Validate ProSomnus Precision Oral Appliance Therapy for the Treatment of Obstructive Sleep Apnea
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus Reports First Quarter 2023 Financial Results
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus Announces Q1 2023 Investor Call and Participation in Upcoming Investor Conferences
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
Study to be Presented at European Respiratory Society and European Sleep Research Society’s Sleep and Breathing 2023 Conference Demonstrates Efficacy of ProSomnus Precision Oral Appliances
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus® Announces Publication of Four Accepted Abstracts in the Journal of Dental Sleep Medicine in Advance of Annual Meeting
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2023
Via Benzinga
ProSomnus® Receives Additional U.S. Utility Patent Covering Iterative Titration Technology for Company’s Novel Precision Sleep Apnea Medical Devices
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 3, 2023
Via Benzinga
ProSomnus Reports Fourth Quarter and Fiscal Year 2022 Financial Results
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
Earnings Scheduled For March 30, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.